Program
donzakimig
Also written as “UCB1381” and “Donzakimig”.
Its studies are mostly in Dermatitis, Atopic, led by UCB.
Furthest: phase 2, since Mar 3, 20222 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 20 open or running | phase 2since Mar 3, 2022 | Mar 3, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 3, 2022First study: phase 2 study in Dermatitis, AtopicFirst studyNCT05277571 · 109 enrolled · United States
- Nov 29, 2024Phase 1 study in Healthy ParticipantsNCT06716879 · 32 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06716879Healthy Participants · United States | 1 | Completed | Apr 4, 2025 | 32 |
| NCT05277571Dermatitis, Atopic · United States | 2 | Completed | Jul 17, 2025 | 109 |
How it is read
Names in the registry
- “UCB1381”, 1 entry
- “Donzakimig”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.